IMPAACT Studies in Development

The study you are looking for is in protocol development.

As the study protocol reaches Version 1.0, a study page will be developed.

  Study Number
(DAIDS ID)
Study Title Status

IMPAACT 2004

(12050)

Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59® in African Infants

In Development

IMPAACT 2003

(11803)

Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant TB Patients (PHOENIx)

In Development

IMPAACT 2002

(12051)

Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the United States

In Development

IMPAACT 2001

(12026)

A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection

In Development

P1108

(11884)

A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Anti-Mycobacterial Activity of Bedaquiline in Combination with Optimized Individualized Multi-Drug Resistant Tuberculosis (MDR-TB) Therapy for the Treatment of HIV-Uninfected and Infected Children and Adolescents with MDR-TB Disease

In Development


Return to the full list of studies

Department of Health and Human ServicesNational Institutes of Health

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.